Definitive Contract 75D30124C19866
Award Date
9/5/24
Potential Completion Date
9/3/29
Potential Value
$7.2M
Federal Agency
CDC Pittsburgh
Awardee
Navitas Clinical Research Inc.
Ultimate Awardee
Not listed
NAICS Category
621511 - Medical Laboratories
PSC Category
R499 - Support- Professional: Other
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Atlanta, GA 30329, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $3,334,668.00 definitive contract awarded by the Centers for Disease Control and Prevention (CDC) to Navitas Clinical Research Inc., doing business as K A I. The contract is a small business set-aside with a firm fixed-price pricing type and a period of performance ending on August 31, 2019. Navitas Clinical Research Inc. is a full-service contract research organization that provides clinical trials management, research and operations support, training, database maintenance, and...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a $4.8 million definitive contract to Vanderbilt University Medical Center to conduct research titled "Innovative Methods to Evaluate the Role of Influenza Vaccines in Attenuating Severe Disease in Adults." The prime contractor will lead a network of 16 academic medical centers as subcontractors to study the effectiveness of influenza vaccines in preventing critical illness. This award was...
<p>The Department of Health and Human Services Centers for Disease Control and Prevention awarded a $250,000.00 Firm Fixed Price Definitive Contract to the National Association of Community Health Centers, Inc. for a VACCINE STUDY. The contract was awarded on September 29, 2017 with a completion date of September 25, 2018. The place of performance is in Atlanta, Georgia. This contract does not have a set-aside designation.</p>
This is a $3,620,000.00 definitive contract awarded by the Centers for Disease Control and Prevention (CDC) to Novartis Vaccines and Diagnostics, Inc. for the "2016 ADULT FLU" program. The contract has a firm fixed price pricing type and an ultimate completion date of February 28, 2017. It is not a set-aside contract. This contract may be related to the CDC's efforts to provide vaccines and diagnostics for influenza preparedness and response, but additional details about the specific...
This firm fixed price contract from the Centers for Disease Control and Prevention (CDC) to Vanderbilt University Medical Center (VUMC) evaluates the effectiveness of vaccines against COVID-19, influenza, and respiratory syncytial virus (RSV) among U.S. adults with severe acute respiratory illness. The $11,908,903.84 potential value contract monitors effectiveness against COVID-19, influenza, and emerging variants, as well as duration of protection. It also conducts RSV surveillance and builds...
This is a definitive contract awarded by the Department of Health and Human Services Centers for Disease Control and Prevention (CDC) in Pittsburgh to Navitas Clinical Research Inc., doing business as K A I, a for-profit contract research organization. The $5,636,638.00 time and materials contract is for epidemiology services, including clinical studies management, oversight, monitoring, safety oversight, training, database and systems maintenance, and general administrative support for the...
This is a $44,980,000.00 definitive contract awarded by the Centers for Disease Control and Prevention (CDC) to Seqirus USA Inc., a foreign-owned, for-profit biotechnology company, for the production and delivery of influenza vaccines. The contract, which does not have a set-aside designation, covers the 2017 adult flu season with a completion date of February 28, 2018. Seqirus, through its Seqirus USA, Inc. division, is a major supplier of influenza vaccines to various federal government...
The Centers for Disease Control and Prevention (CDC) awarded an $8.4 million cost-plus-fixed-fee delivery order contract to the National Opinion Research Center (NORC) to provide task order 20 NIS-FLU 2022 services from September 1, 2022 through August 31, 2023. NORC will perform the work out of its Chicago, Illinois office. As the prime contractor, NORC will likely utilize survey research methodologies to assist the CDC with monitoring influenza-like illnesses in the United States, though...
The Centers for Disease Control and Prevention (CDC) awarded a $658,016 definitive contract to Marshfield Clinic, Inc. for "OPTIMAL STRATEGIES TO ESTIMATE THE RELATIVE EFFECTIVENESS OF INFLUENZA VACCINES". This contract, which has a term ending on March 17, 2025, is not set aside. Marshfield Clinic, Inc., a non-profit healthcare organization, will be providing services related to evaluating the effectiveness of influenza vaccines. This contract is part of a larger Vaccine Safety...
The Centers for Disease Control and Prevention (CDC) awarded a $728,000 firm fixed price definitive contract to Quest Diagnostics Incorporated for de-identified specimen remnants to support the National Center for Immunization and Respiratory Diseases (NCIRD). As the prime contractor, Quest Diagnostics will provide de-identified biological specimens to NCIRD through April 2021. No subcontractors or set aside designations were indicated. NCIRD conducts public health surveillance, laboratory...